Farmer P M, Mulakkan T
Department of Pathology, North Shore University Hospital, Cornell University Medical College, Manhasset, NY 11030.
Ann Clin Lab Sci. 1990 Mar-Apr;20(2):91-7.
Hepatic encephalopathy remains a complex clinicopathological problem. Much is known about the biochemical derangements in liver, blood, and brain. The precise pathogenetic mechanism for central nervous system dysfunction remains to be determined. Ammonia continues to be considered as an important neurotoxin and may act synergistically with other toxic substances. Disturbances of amino acid balance may result in a disproportion of inhibitory and excitatory neurotransmitters in the brain. Alternatively, some amino acids may act as false neurotransmitters. Recent clinical and laboratory data have advanced the hypothesis that gamma-aminobutyric acid (GABA) absorbed from the gut may enter the brain and exert a profound inhibitory effect. Drugs which antagonize the GABA-benzodiazepate receptor may offer symptomatic improvements in hepatic encephalopathy.
肝性脑病仍然是一个复杂的临床病理问题。人们对肝脏、血液和大脑中的生化紊乱了解很多。中枢神经系统功能障碍的确切发病机制仍有待确定。氨仍然被认为是一种重要的神经毒素,可能与其他有毒物质协同作用。氨基酸平衡的紊乱可能导致大脑中抑制性和兴奋性神经递质失衡。另外,一些氨基酸可能充当假性神经递质。最近的临床和实验室数据支持了这样一种假说,即从肠道吸收的γ-氨基丁酸(GABA)可能进入大脑并产生深远的抑制作用。拮抗GABA-苯二氮䓬受体的药物可能会使肝性脑病的症状得到改善。